» » » Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

, Edit
In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Latest Science News -- ScienceDaily https://ift.tt/317NlC5

SUBSCRIBE TO OUR NEWSLETTER

Related Posts :

Admin

“Work hard in silence, let your success be your noise"

0 Response to "Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations"

Post a Comment

Subscribe to: Post Comments (Atom)

ad

Search Your Job